Trinity Biotech's CGM+ Tech Validates Ability to Distinguish False Glucose Alerts in Clinical Trial
Event summary
- Trinity Biotech's CGM+ technology successfully distinguished nocturnal compression-related false low glucose events in a clinical trial using over 5,000 hours of wear data.
- The study demonstrated the ability to reduce sleep disruption and avoidable glucose variability caused by false alarms in conventional CGMs.
- CGM+ combines glucose measurements with additional physiological signals via a proprietary multi-sensor architecture.
- Trinity Biotech aims to incorporate this capability into its solution as it moves toward pivotal trial and regulatory submission.
The big picture
Trinity Biotech's success in identifying false glucose alerts addresses a critical limitation of conventional CGMs, potentially improving user experience and expanding its market reach. The multi-sensor approach positions the company to compete more effectively in the rapidly growing diabetes management sector, where accuracy and contextual insights are increasingly valued.
What we're watching
- Market Differentiation
- Whether Trinity Biotech can sustain its competitive edge in the $15 billion global CGM market with its multi-sensor approach.
- Regulatory Progress
- The pace at which CGM+ moves through pivotal trials and regulatory approvals to commercialize the nocturnal compression-low detection feature.
- Partnership Expansion
- How Trinity Biotech leverages richer data insights from CGM+ to attract automated insulin delivery system providers as partners.
Related topics